Brief: Shanghai Henlius Biotech Posts FY Revenue RMB 5,724.4 Million
24/03/2025 10:43
Mar 24 (Reuters) - Shanghai Henlius Biotech FY gross profit RMB 4,184.7 million. FY operating income RMB 5,724.4 million FY revenue RMB 5,724.4 million
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln